ANANDA Scientific Announces First Patient Enrolled in FDA-approved Clinical Trial Evaluating a Potential New Treatment for Social Anxiety Disorder (SAD)
ANANDA Scientific Announces FDA Approval of the IND for a Clinical Trial exploring treatment of Social Anxiety Disorder (SAD)
ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced the first patient enrolled in the clinical trial evaluating...
GREENWOOD VILLAGE, Colo. & LOS ANGELES--(BUSINESS WIRE)--ANANDA Scientific Inc., (a biotech pharma company) today announced approval by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. The study will be done at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA.
REENWOOD VILLAGE, Colo. & NEW YORK--(BUSINESS WIRE)--ANANDA Scientific Inc., a biotech pharma company, announced a clinical trial to evaluate Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology for Opioid Use Disorder. An Investigational New Drug (IND) application has been approved by the U.S. Food and Drug Administration (FDA) for this trial.
GREENWOOD VILLAGE, Colo. & LOS ANGELES--(BUSINESS WIRE)--ANANDA Scientific Inc., a biotech pharma company, today announced the commencement of a clinical trial to be done in collaboration with the Jane and Terry Semel Institute at David Geffen School of Medicine at UCLA, to evaluate Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. An Investigational New Drug (IND) application is being submitted to the U.S. Food and Drug Administration (FDA) for this trial.
ANANDA Scientific Inc. , a pharmaceutical biotechnology company, and the NYU Grossman School of Medicine announced today that the first patient has been enrolled in the clinical study that will evaluate Nantheia ™ A1002N5S , a Investigational drug using cannabidiol withANANDA's proprietary Liquid Structure ™ delivery technologyas a treatment for symptoms of post-traumatic stress disorder (PTSD) and neurocognitive impairment in patients with PTSD and PTSD with traumatic brain injury (TBI) concomitant.
ANANDA Scientific Inc., a biotech pharmaceutical company, and NYU Grossman School of Medicine today announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology as a treatment for Post-Traumatic Stress Disorder (PTSD) symptoms and Neurocognitive Impairment in patients with PTSD and with PTSD comorbid with Traumatic Brain Injury (TBI).